Q4'FY24 Earnings Call Supplemental Presentation August 14, 2024 Forward-looking Statements This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Safe Harbor Statement Statements in this presentation (including the oral commentary that accompanies it) that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in ...

14% Revenue and 8% Orders Growth in Q4; Company issues FY25 GuidanceMADISON, Wis., Aug. 14, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal 2024, ended June 30, 2024.Fourth Quarter Fiscal 2024 SummaryNet revenue of $134.3 million, an increase of 13.5 percent from the same period in the prior fiscal year. Net revenue on a constant currency basis was $136.7 million, which represents a 15.6 percent increase versus the same period in th ...

Exhibit 99.1 Accuray Reports Fourth Quarter and Fiscal 2024 Financial Results 14% Revenue and 8% Orders Growth in Q4; Company issues FY25 Guidance MADISON, Wisconsin, August 14, 2024 — Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal 2024, ended June 30, 2024. Fourth Quarter Fiscal 2024 Summary • Net revenue of $134.3 million, an increase of 13.5 percent from the same period in the prior fiscal year. Net revenue on a constant currency basis was $136.7 mi ...

New Technology Provides Advanced Patient Positioning Capabilities With the Radixact System, Making it Easier to Deliver Fast and Effective Radiotherapy TreatmentsMADISON, Wis. and DAYTONA BEACH, Fla., Aug. 13, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) and Halifax Health, in Volusia County, Florida, announced today that the Charles L. and Miki N. Grant Cancer Center for Hope medical team is the first in the U.S. to treat cancer patients using the Accuray Radixact® System with VitalHold™* techn ...

MADISON, Wis., July 31, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the fourth quarter of fiscal year 2024, ended June 30, 2024, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on August 14, 2024.The conference call dial-in numbers are (833) 316-0563 (USA) or (412) 317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. Th ...

When it comes to investing in top penny stocks, a word of caution.Always do your due diligence before buying. Make sure it has volume. Know upfront that you can lose a lot of money. And don’t get caught up in the promotional promises of turning $10,000 into millions without first doing your homework. As I’ll repeat below, penny stocks are frequently the playground for scam artists and market manipulators.Sure, some penny stocks turned out to be massive success stories, like Apple (NASDAQ:AAPL), Ford (NYSE:F ...

The Radixact System will be supplied with ClearRT®, Synchrony®, and the VOLO™ Ultra Optimizer to enhance radiation treatment delivery precision and speedHeidelberg University Hospital is recognized worldwide for excellence in patient care and practice changing researchMADISON, Wis., June 27, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that long-term customer Heidelberg University Hospital in Heidelberg, Germany, has selected the company's Radixact® System, equipped with its prop ...

Company Developments - Accuray Incorporated (ARAY) has entered into an agreement with TrueNorth Medical Physics LLC to enhance the capabilities of radiation oncology departments, providing supplementary services to hospitals [1][2] - TrueNorth will support the commissioning, physics, and dosimetry of Accuray's TomoTherapy, Radixact, and CyberKnife platforms, offering customized services tailored to hospital needs [2] - Accuray has been actively forming partnerships, including a collaboration with Oncopole Claudius Regaud and Airbus SAS to develop an AI-driven solution for predicting radiotherapy system performance [3] Industry Prospects - The global radiation therapy market, valued at $7.3 billion in 2022, is projected to grow at a rate of 8%, reaching over $14.9 billion by 2032, driven by increased efficiency and market demand [4] Notable Developments - In June, Accuray received approval from the Chinese National Medical Products Administration for its Precision Treatment Planning System, enhancing treatment accuracy and expanding access to care for cancer patients in China [5] - New data presented at the 2024 Radiosurgery Society Meeting supports the use of the CyberKnife System for treating high-risk and recurrent prostate cancer [5] Price Performance - Over the past six months, ARAY's shares have decreased by 34.5%, contrasting with a 5.8% increase in the industry and a 15.2% rise in the S&P 500 [6]

MADISON, Wis., June 20, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today an agreement with TrueNorth Medical Physics LLC to provide radiation oncology departments with third-party support designed to enhance their department's capabilities. Under the terms of the agreement, TrueNorth Medical Physics will offer services that are complementary and supplementary to those supplied by Accuray, acting as an extension of the hospital team – on-site, remote or hybrid – to help ensure they ha ...

Accuray Incorporated (ARAY) recently announced that the Chinese National Medical Products Administration (NMPA) approved the registration dossier of the Accuray Precision Treatment Planning System (TPS).The CNNC-Accuray joint venture Tomo C radiation therapy system and the Accuray Precision TPS are now compatible. These are likely to provide medical teams with a new way to administer highly accurate and precise radiation treatments, as well as expand access to care for more cancer patients in China.More on ...